Unknown

Dataset Information

0

Kinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their Infants.


ABSTRACT: BACKGROUND:We evaluated the immunogenicity of trivalent inactivated influenza vaccine (IIV3) in pregnant women with and those without human immunodeficiency virus (HIV) infection and the persistence of hemagglutination-inhibiting antibodies in mothers and infants. METHODS:Antibodies were measured before vaccination, 1 month after vaccination, at delivery, and at postpartum week 24 in mothers and within 1 week of birth and at 8, 16, and 24 weeks of age in infants. RESULTS:We enrolled 98 HIV-uninfected and 100 HIV-infected pregnant women, including 93% with a CD4(+) T-cell count of ? 200 cells/µL. Compared with HIV-uninfected women, HIV-infected women had lower seroconversion rates (ranging from 63%-92% vs 36%-40%), lower antibody titers through postpartum week 24, and overlapping antibody half-lives (ranging from 106-121 vs 87-153 days). Infant titers were lower than the maternal titers within 1 week of delivery, regardless of vaccine strain and HIV exposure status. Compared with HIV-unexposed infants, HIV-exposed infants had a similar transplacental influenza virus antibody transfer ratio, lower titers, and a lower frequency of titers ? 1:40 (ranging from 82%-95% vs 43%-79%) at birth and higher antibody half-lives (ranging from 43-45 vs 56-65 days). CONCLUSIONS:Compared with HIV-uninfected pregnant women, HIV-infected pregnant women had lower antibody responses and persistence. Compared with HIV-unexposed infants, HIV-exposed infants had lower antibody levels at birth but similar antibody levels after 8 weeks of life. Early IIV3 administration during pregnancy did not decrease antibody titers among infants at birth.

SUBMITTER: Nunes MC 

PROVIDER: S-EPMC4655859 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Kinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their Infants.

Nunes Marta C MC   Cutland Clare L CL   Dighero Bonnie B   Bate Janie J   Jones Stephanie S   Hugo Andrea A   van Niekerk Nadia N   Kuwanda Locadiah L   Izu Alane A   Weinberg Adriana A   Madhi Shabir A SA  

The Journal of infectious diseases 20150616 12


<h4>Background</h4>We evaluated the immunogenicity of trivalent inactivated influenza vaccine (IIV3) in pregnant women with and those without human immunodeficiency virus (HIV) infection and the persistence of hemagglutination-inhibiting antibodies in mothers and infants.<h4>Methods</h4>Antibodies were measured before vaccination, 1 month after vaccination, at delivery, and at postpartum week 24 in mothers and within 1 week of birth and at 8, 16, and 24 weeks of age in infants.<h4>Results</h4>We  ...[more]

Similar Datasets

| S-EPMC4309889 | biostudies-other
| S-EPMC6312282 | biostudies-literature
| S-EPMC10681861 | biostudies-literature
| S-EPMC4388400 | biostudies-literature
| S-EPMC9342588 | biostudies-literature
| PRJEB25404 | ENA
| S-EPMC7062446 | biostudies-literature
| S-EPMC6986709 | biostudies-literature
| S-EPMC4474558 | biostudies-literature
| S-EPMC8554191 | biostudies-literature